Governors Lane’s Orchestra BioMed OBIO Stock Holding History

Governors Lane’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-250,000	Closed	-$2.49M	–	178
2022 Q2	$2.49M	Hold	250,000	–	–	0.2%	138
2022 Q1	$2.48M	Hold	250,000	–	–	0.18%	134
2021 Q4	$2.52M	Hold	250,000	–	–	0.15%	157
2021 Q3	$2.47M	Hold	250,000	–	–	0.16%	121
2021 Q2	$2.55M	Buy	+250,000	New	+$2.59M	0.18%	115
2021 Q1	–	Sell	-131,250	Closed	-$1.68M	–	192
2020 Q4	$1.68M	Sell	131,250 -43,750	-25%	-$499K	0.14%	84
2020 Q3	$1.93M	Buy	+175,000	New	+$1.97M	0.17%	73

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Governors Lane's OBIO Position: Q3 2022 in Review

Governors Lane sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 250,000 shares — an estimated $2.49M sold.

Governors Lane first reported a position in OBIO in Q3 2020 and held it in 7 quarters. The position peaked at $2.55M in Q2 2021. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

Governors Lane reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
Governors Lane sold 250,000 Orchestra BioMed shares in Q3 2022, an estimated $2.49M.
Governors Lane first reported a position in Orchestra BioMed in Q3 2020 and held it in 7 quarters.
Governors Lane's Orchestra BioMed position peaked at $2.55M in Q2 2021.
23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Governors Lane's 13F filing for Q3 2022, filed 14 Nov 2022.